Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans

Cost Savings Of $20m Annually Targeted; Portfolio Also Rationalized

 
• By Dean Rudge
  
structuring
Lannett cited challenging business conditions as it wielded the axe • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Business

More from Generics Bulletin